Enhanced Immunochemistry Analyzers Offer Workstation Consolidation and Efficiency

The analyzers have an extensive menu of more than 170 assays. Laboratories will be able to reduce labor, optimize throughput, and enhance overall productivity, while standardizing data management processes and optimizing inventory control. The new features will minimize training, and reduce inventory costs and sample contamination potential, resulting in improved performance and outcomes for laboratories, physicians, and patients.

Two new assays recently added were the HE4 for early detection and monitoring of ovarian cancer and the human immunodeficiency virus (HIV) antigen/antibody Combo Assay to identify early HIV infections. Additionally, Abbott has more than a dozen novel biomarkers in development, and several are expected to be introduced within months of the introduction of the analyzers.


"According to the Health and Human Services Administration on Aging, one in five Americans will be age 65 and older in 20 years. It's well documented that older people are the largest consumers of health care services, and the huge growth in this age group will likely generate significant new demand for routine lab tests and follow-up testing for diabetes, cancer and other conditions," said Brian Blaser, senior vice president, diagnostics, Abbott. "Already stressed with finding ways to deal with diminishing resources and a serious shortage of trained staff, laboratories are turning to diagnostics manufacturers for technologies and capabilities they need to operate effectively and survive in this environment."

Architectplus was showcased for the first time at the annual American Association for Clinical Chemistry Lab Expo, which was held in Anaheim, (CA, USA) from July 25-29, 2010.

Related Links:
Abbott
American Association for Clinical Chemistry